Safety and Preliminary Efficacy of ATG-017 Monotherapy in Advanced Solid Tumors and Hematological Malignancies
Status:
Recruiting
Trial end date:
2023-08-20
Target enrollment:
Participant gender:
Summary
This is a Phase I, multi-center, open-label study of ATG-017 administered orally, alone in
patients with advanced solid tumors and hematological malignancies. The study design includes
a Dose Escalation Phase and Dose Expansion Phase.